Sage Therapeutics announced that its board of directors has unanimously rejected the proposal it received from Biogen on Jan. 10, 2025, to acquire all outstanding shares of Sage not already owned by Biogen for $7.22 per share, representing an equity value of about $469 million.
Biogen and Human Immunology Biosciences (HI-Bio), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases (IMDs), have entered into a definitive agreement. Biogen has agreed to acquire HI-Bio for $1.15 billion (€1.06 billion) upfront and up to $650 million (€600.5 million) in potential milestone payments.
Biogen and Reata Pharmaceuticals announced late last week that Biogen has agreed to acquire Reata for €156.51 per share in cash, reflecting an enterprise value of approximately €6.6 billion.
US biotech Sangamo Therapeutics is studying alternative options to advance its neurological disease programs after both Novartis and Biogen ended their respective collaborations. The California-based company said options could include potentially developing the programs internally, or with another partner.
The US Court of Appeals for the Federal Circuit on Sept. 28 set aside a decision of the US district court of New Jersey in Newark, reversing the district court’s earlier decision in favor of Biogen in a damages claim against Germany’s Merck Serono (known as EMD Serono in North America).
